Eris Lifesciences Limited has scheduled a Board of Directors meeting on Wednesday, July 29, 2026. The primary agenda of the meeting is to consider and approve both the standalone and consolidated unaudited financial results for the quarter ended June 30, 2026 (Q1 FY27).
The company had previously informed via letter dated June 26, 2026 about the closure of the trading window for insider trading purposes. The trading window has been closed since July 1, 2026, and will remain closed until 48 hours after the declaration of the financial results. This closure is in compliance with the SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal Policy on 'Code of Conduct to Regulate, Monitor and Report Trading by its Designated Persons and immediate relatives of Designated Persons'.
The disclosure has been formally submitted to both BSE Limited and National Stock Exchange of India Limited as required under listing regulations.
The financial results themselves are not disclosed in this intimation and will be published separately after board approval.